With the introduction of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, sodium-glucose cotransporters-2 (SGLT2) inhibitors, and glucagon-like peptide-1 receptor (GLP-1) agonists more treatment options are becoming available for patients with cardiovascular disease. The gene discussed is PCSK9; the disease is cardiovascular disorder.